573 completed, 158 recruiting, 145 terminated, 112 unknown. 496 Phase 1, 479 Phase 2, 89 Phase 3, 78 Not applicable, 32 Early Phase 1.
Follow Epstein-Barr Virus Infections: new trials by email Literature Review of Epstein-Barr Virus Infections trials Research Report on Epstein-Barr Virus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 271 | 2027-07-27 | 2026-11-17 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-11-13 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL) Asciminib, Inotuzumab ozogamicin - B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Recruiting | Sunil G. Iyer | 45 | 2027-03-31 | 2026-11-13 |
| Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL | Phase 1 | Not yet recruiting | Medical University of South Carolina | 18 | 2027-02-01 | 2026-11-13 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Study Of KITE-753 in R/R B-Cell ALL KITE-753 - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 18 | 2026-12-31 | 2026-09-11 |
| Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults MVA-BN-EBV, Placebo - Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Bavarian Nordic | 15 | 2026-12-15 | 2026-10-22 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia Rituximab - PTLD, Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Jennifer Amengual | 28 | 2026-12-01 | 2026-09-17 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| BLinatumomab and iNKT in Relapsed B-Cell ALL Invariant Natural Killer T Cell Therapy - B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia) | Phase 1 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 13 | 2026-12-01 | 2026-11-05 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-12-01 | 2026-11-09 |
| mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults VXCO-102, Placebo - EBV | Phase 1 | Recruiting | Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company | 82 | 2026-11-16 | 2026-10-26 |
| EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases Donor-derived ex-vivo expanded EBV Tscm CTL - EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Basel, Switzerland | 10 | 2026-11-01 | 2025-03-03 |
| 25BT056: Basket Study of Viral Cytotoxic T Lymphocytes Virus-Specific Cytotoxic T Lymphocytes (vCTLs) - EBV Viremia, CMV Viremia | Early Phase 1 | Not yet recruiting | Children's Hospital of Philadelphia | 35 | 2026-11-01 | 2026-10-22 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| Epstein-Barr Virus Antibodies in Egyptian Patients With Multiple Sclerosis Multiple Sclerosis, Epstein-Barr Virus Infections | Not yet recruiting | Assiut University | 140 | 2026-10-01 | 2026-09-29 |
Showing 20 of 1148. Sign in to see all of them.
Burkitt Lymphoma (977) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (585) · Lymphoma, Large B-Cell, Diffuse (574) · Lymphoma, Follicular (522) · Lymphoma, Mantle-Cell (508) · Lymphoma, Non-Hodgkin (502) · Leukemia, Lymphocytic, Chronic, B-Cell (464) · Lymphoma, B-Cell, Marginal Zone (458) · Lymphoma (447) · Lymphoma, Large-Cell, Immunoblastic (445) · Hodgkin Disease (351) · Leukemia (267) · Leukemia, Myeloid, Acute (252) · Lymphoma, T-Cell, Cutaneous (252) · Multiple Myeloma (248)
DNA Virus Infections (1148) · Herpesviridae Infections (1145) · Tumor Virus Infections (1142) · Virus Diseases (1136) · Infections (1111) · Immune System Diseases (1039) · Hemic and Lymphatic Diseases (1027) · Lymphatic Diseases (1024) · Neoplasms by Histologic Type (1022) · Immunoproliferative Disorders (1021) · Lymphoproliferative Disorders (976) · Neoplasms (976) · Lymphoma, B-Cell (904) · Hematologic Diseases (730)
Cyclophosphamide (226) · Rituximab (121) · Etoposide (104) · Methotrexate (95) · Vincristine (95) · Peripheral Blood Stem Cell Transplantation (94) · Cytarabine (93) · Filgrastim (92) · fludarabine phosphate (85) · Doxorubicin (73) · Prednisone (69) · Radiotherapy (67) · Dexamethasone (62) · Cyclosporine (53) · Mycophenolic Acid (53)
National Cancer Institute (NCI) (117) · Fred Hutchinson Cancer Center (59) · M.D. Anderson Cancer Center (34) · City of Hope Medical Center (28) · Memorial Sloan Kettering Cancer Center (27) · Children's Oncology Group (25) · Masonic Cancer Center, University of Minnesota (25) · Case Comprehensive Cancer Center (22) · Roswell Park Cancer Institute (16) · Mayo Clinic (15) · National Institutes of Health Clinical Center (CC) (15) · Medical College of Wisconsin (14) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (14) · Alliance for Clinical Trials in Oncology (13) · Baylor College of Medicine (13)
United States (800) · China (133) · Canada (75) · France (56) · Italy (48) · Germany (44) · United Kingdom (44) · Australia (38) · Spain (31) · Puerto Rico (27) · Switzerland (26) · Belgium (24) · Netherlands (23) · South Korea (20) · Israel (15)
Ajay Gopal (9) · Elias Jabbour (7) · Helen E Heslop, MD (6) · Philip L. McCarthy, MD (6) · Christos E. Emmanouilides, MD (5) · David Maloney (5) · Elias Jabbour, MD (5) · Ibrahim Aldoss (5) · Roger Strair, MD, PhD (5) · Brenda Sandmaier (4) · Christopher J Melani, M.D. (4) · Claudio G. Brunstein, MD, PhD (4) · Ephraim J. Fuchs, MD (4) · Helen Heslop, MD (4)
PMID 41671463, PMID 35622074, PMID 34515338, PMID 32499241, PMID 32589970, PMID 38551807, PMID 17242396, PMID 19949018, PMID 20028764, PMID 21527516, PMID 22002018, PMID 22337718, PMID 24862638, PMID 33308471, PMID 33496754, PMID 34353848, PMID 34432863, PMID 34473237, PMID 34687939, PMID 34806163, PMID 34889384, PMID 35422096, PMID 35489026, PMID 35732829, PMID 36736781, PMID 37486616, PMID 37890117, PMID 39121442, PMID 40367950, PMID 41774854, PMID 42341322, PMID 10552943, PMID 10632319, PMID 10764422, PMID 10820362, PMID 11410496, PMID 11600602, PMID 11756154, PMID 12121233, PMID 12171484, PMID 12525530, PMID 1403051, PMID 14508361, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15042678, PMID 15107815, PMID 15459300, PMID 15466923
P30CA033572 (24), P30CA015704 (19), P30CA043703 (17), U10CA032102 (15), P30CA006973 (13), P30CA015083 (12), U10CA180886 (12), P30CA022453 (11), P30CA072720 (9), U01CA097452 (9), U10CA098543 (9), P30CA016672 (8), 2023 (7), P30CA068485 (7), U10CA031946 (7)